Core Viewpoint - Zynex, Inc. is under investigation for potential claims related to a class action complaint alleging that the company's board of directors breached their fiduciary duties by misleading investors about financial performance and operational practices [1][2]. Summary by Relevant Sections Allegations of Misconduct - The complaint claims that Zynex's management engaged in practices that artificially inflated the company's stock price through false statements regarding financial performance and compliance with insurance reimbursement policies [2]. - It is alleged that Zynex operated a systemic "oversupplying scheme," shipping excessive quantities of supplies to patients and billing insurers significantly more than necessary [2]. Financial Impact and Regulatory Scrutiny - The extent of Zynex's misconduct was revealed on March 11, 2025, when the company announced a revenue shortfall due to slower payments from insurers, particularly Tricare, which accounted for 20-25% of its annual revenue [3]. - Following the announcement, Zynex's stock price fell by $3.59 per share, or 51.3%, closing at $3.41 per share, indicating a severe loss of shareholder value and highlighting the company's exposure to regulatory and financial risks [4].

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against Zynex, Inc. (NASDAQ: ZYXI), a medical device manufacturer specializing in electrotherapy devices, alleging that the company and certain of its top executives misled investors by overstating revenue through the practice of shipping excessive and unnecessary supplies to patients. The complaint, Tuncel v. Zynex, Inc., No. 25-cv-00913, filed in the U.S. District Court for the District of Colorado, seeks to represent in ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) investors of a class action representing investors that bought securities between March 13, 2023 and March 11, 2025, inclusive (the "Class Period"). Zynex investors have until May 19, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by ph ...